A comprehensive outlook on intracerebral therapy of malignant gliomas

Critical Reviews in Oncology/Hematology

Volumn 80, Issue 1, 2011, Pages 54-68

  Buonerba, Carlo ^a   Di Lorenzo, Giuseppe ^a,b   Marinelli, Alfredo ^a,b   Federico, Piera ^a   Palmieri, Giovannella ^a,b   Imbimbo, Martina ^a   Conti, Pio ^c   Peluso, Gianfranco ^d   De Placido, Sabino ^a   Sampson, John H ^e  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b Centro di Riferimento Tumori Rari (CRTR) Regione Campania   (Italy)

^c UNIVERSITY OF CHIETI   (Italy)

^d INSTITUTE OF PROTEIN BIOCHEMISTRY   (Italy)

^e DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Brain neoplasm; Convection enhanced delivery; Drug delivery system; IPlan Flow

Indexed keywords

6 O BENZYLGUANINE; BLEOMYCIN; CARMUSTINE; CINTREDEKIN BESUDOTOX; CISPLATIN; COTARA; DOTAGA SP BI 213; DOTAGA SP LUT 177; DOTAGA SP Y 90; DOXORUBICIN; DRUG CARRIER; FLUOROURACIL; MITOXANTRONE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 81C6 AT 211; MONOCLONAL ANTIBODY 81C6 I 131; NBI 3001; NIMOTUZUMAB RE 188; PACLITAXEL; PLACEBO; RADIOPHARMACEUTICAL AGENT; TEMOZOLOMIDE; TF CRM 107; TOXIN; TP 38; TRANSMID; UNCLASSIFIED DRUG;

ASEPTIC MENINGITIS; BIFRONTAL HEADACHE; BLOOD BRAIN BARRIER; BLOOD TOXICITY; BONE MARROW TOXICITY; BRAIN EDEMA; BRAIN INFECTION; BRAIN INJURY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CHEMICAL MENINGITIS; CLINICAL RESEARCH; CONFUSION; CONTINUOUS INFUSION; CONVECTION ENHANCED DELIVERY; DECUBITUS; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG POTENTIATION; EDEMA; FATIGUE; FOOD AND DRUG ADMINISTRATION; GLIOBLASTOMA; HEADACHE; HEMIPARESIS; HEMIPLEGIA; HUMAN; HYDROCEPHALUS; INFECTION; INTRACEREBRAL DRUG ADMINISTRATION; INTRACRANIAL HYPERTENSION; ISOTOPE LABELING; LIQUORRHEA; MENINGITIS; MULTIPLE CYCLE TREATMENT; NEUROLOGIC DISEASE; NEUROTOXICITY; PERIFOCAL EDEMA; PERITUMORAL INJURY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; REVIEW; SEIZURE; SKIN INFECTION; SKIN NECROSIS; SURVIVAL TIME;

ANTINEOPLASTIC AGENTS; BRACHYTHERAPY; BRAIN NEOPLASMS; CONVECTION; DRUG ADMINISTRATION ROUTES; DRUG DELIVERY SYSTEMS; GLIOMA; HUMANS; IMMUNOTOXINS; MAGNETIC RESONANCE IMAGING;

EID: 80053131718     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2010.09.001     Document Type: Review

References (64)

1. Stupp R., Roila F. Malignant glioma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009, 20(Suppl.):S126-S128. ESMO Guidelines Working Group.
2. Stupp R., Mason W.P., van den Bent M.J., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005, 352:987-996.
3. Hochberg F.H., Pruitt A. Assumptions in the radiotherapy of glioblastoma. Neurology 1980, 30:907-911.
4. Nieder C., Grosu A.L., Molls M. A comparison of treatment results for recurrent malignant gliomas. Cancer Treatment Rev 2000, 26:397-409.
5. Walter K.A., Tamargo R.J., Olivi A., Burger P.C., Brem H. Intratumoral chemotherapy. Neurosurgery 1995, 37:1128-1145.
6. Chamberlain M.C. Combined-modality treatment of leptomeningeal gliomatosis. Neurosurgery 2003, 52:324-329.
7. Misra A., Ganesh S., Shahiwala A., Shah S.P. Drug delivery to the central nervous system: a review. J Pharm Pharm Sci 2003, 6:252-273.
8. Bobo R.H., Laske D.W., Akbasak A., Morrison P.F., Dedrick R.L., Oldfield E.H. Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci USA 1994, 91:2076-2080.
9. Sampson J.H., Archer G., Pedain C., et al. Poor drug distribution as a possible explanation for the results of the PRECISE trial. J Neurosurg 2009, [December 18; Epub ahead of print].
10. Engelhard H.H. The role of interstitial BCNU chemotherapy in the treatment of malignant glioma. Surg Neurol 2000, 53:458-464.
11. Berweiler U., Krone A., Tonn J.C. Reservoir systems for intraventricular chemotherapy. J Neurooncol 1998, 38:141-143.
12. Patchell R.A., Regine W.F., Ashton P., et al. A phase I trial of continuously infused intratumoral bleomycin for the treatment of recurrent glioblastoma multiforme. J Neurooncol 2002, 60:37-42.
13. Jain J.P., Modi S., Domb A.J., Kumar N. Role of polyanhydrides as localized drug carriers. J Control Release 2005, 103:541-563.
14. Brem H., Kader A., Epstein J.I., et al. Biocompatibility of a biodegradable, controlled-release polymer in the rabbit brain. Sel Cancer Ther 1989, 5:55-65.
15. Sipos E.P., Tyler B., Piantadosi S., Burger P.C., Brem H. Optimizing interstitial delivery of BCNU from controlled release. Cancer Chemother Pharmacol 1997, 39:383-389.
16. Bidros D.S., Vogelbaum M.A. Novel drug delivery strategies in neuro-oncology. Neurotherapeutics 2009, 6:539-546.
17. Domb A.J., Rock M., Perkin C., et al. Excretion of a radiolabelled anticancer biodegradable polymeric implant from the rabbit brain. Biomaterials 1995, 16:1069-1072.
18. Brem H., Tamargo R.J., Olivi A., et al. Biodegradable polymers for controlled delivery of chemotherapy with and without radiation therapy in the monkey brain. J Neurosurg 1994, 80:283-290.
19. Sawyer A.J., Piepmeier J.M., Saltzman W.M. New methods for direct delivery of chemotherapy for treating brain tumors. Yale J Biol Med 2006, 79:141-152.
20. Menei P., Capelle L., Guyotat J., et al. Local and sustained delivery of 5-fluorouracil from biodegradable microspheres for the radiosensitization of malignant glioma: a randomized phase II trial. Neurosurgery 2005, 56:242-248.
21. Roullin V.G., Deverre J.R., Lemaire L., et al. Anti-cancer drug diffusion within rat brain tissue: an experimental study using [3H]-(6)-5-fluorouracil-loaded PLGA microspheres. Eur J Pharm Biopharm 2002, 53:293-299.
22. Sheleg S.V., Korotkevich E.A., Zhavrid E.A., et al. Local chemotherapy with cisplatin-depot for glioblastoma multiforme. J Neurooncol 2002, 60:53-59.
23. Ferroli P., Broggi M., Franzini A., et al. Surgifoam and mitoxantrone in the glioblastoma multiforme postresection cavity: the first step of locoregional chemotherapy through an ad hoc-placed catheter: technical note. Neurosurgery 2006, 59:E433-E434.
24. Raghavan R., Brady M.L., Rodríguez-Ponce M.I., Hartlep A., Pedain C., Sampson J.H. Convection-enhanced delivery of therapeutics for brain disease, and its optimization. Neurosurg Focus 2006, 20:E12.
25. Allard E., Passirani C., Benoit J.P. Convection-enhanced delivery of nanocarriers for the treatment of brain tumors. Biomaterials 2009, 30:2302-2318.
26. Tanner P.G., Holtmannspötter M., Tonn J.C., Goldbrunner R. Effects of drug efflux on convection-enhanced paclitaxel delivery to malignant gliomas: technical note. Neurosurgery 2007, 61:E880-E882.
27. Varenika V., Dickinson P., Bringas J., et al. Detection of infusate leakage in the brain using real-time imaging of convection-enhanced delivery. J Neurosurg 2008, 109:874-880.
28. Sampson J.H., Brady M.L., Petry N.A., et al. Intracerebral infusate distribution by convection-enhanced delivery in humans with malignant gliomas: descriptive effects of target anatomy and catheter positioning. Neurosurgery 2007, 60:S89-S98.
29. Fiandaca M.S., Forsayeth J.R., Dickinson P.J., Bankiewicz K.S. Image-guided convection-enhanced delivery platform in the treatment of neurological diseases. Neurotherapeutics 2008, 5:123-127.
30. Sampson J.H., Raghavan R., Brady M.L., et al. Clinical utility of a patient-specific algorithm for simulating intracerebral drug infusions. Neuro Oncol 2007, 9:343-353.
31. Lonser R.R., Warren K.E., Butman J.A., et al. Real-time image-guided direct convective perfusion of intrinsic brainstem lesions. Technical note. J Neurosurg 2007, 107:190-197.
32. Ding D., Kanaly C.W., Bigner D.D., et al. Convection-enhanced delivery of free gadolinium with the recombinant immunotoxin MR1-1. J Neurooncol 2009, [November; Epub ahead of print].
33. Voges J., Reszka R., Gossmann A., et al. Imaging-guided convection-enhanced delivery and gene therapy of glioblastoma. Ann Neurol 2003, 54:479-487.
34. Sampson J.H., Raghavan R, Provenzale J.M., et al. Induction of hyperintense signal on T2-weighted MR images correlates with infusion distribution from intracerebral convection-enhanced delivery of a tumor-targeted cytotoxin. Am J Roentgenol 2007, 188(March):703-709.
35. Lidar Z., Mardor Y., Jonas T., et al. Convection-enhanced delivery of paclitaxel for the treatment of recurrent malignant glioma: a phase I/II clinical study. J Neurosurg 2004, 100:472-479.
36. Brem H., Piantadosi S., Burger P.C., et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group. Lancet 1995, 345:1008-1012.
37. Westphal M., Hilt D.C., Bortey E., et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol 2003, 5:79-88.
38. Quinn J.A., Jiang S.X., Carter J., et al. Phase II trial of Gliadel plus O6-benzylguanine in adults with recurrent glioblastoma multiforme. Clin Cancer Res 2009, 15:1064-1068.
39. La Rocca R.V., Mehdorn H.M. Localized BCNU chemotherapy and the multimodal management of malignant glioma. Curr Med Res Opin 2009, 25:149-160.
40. La Rocca R., Vitaz T.W., Villanueva W., et al. A phase 2 study of multi modal therapy with surgery, carmustine wafer, radiation therapy, and temozolomide in patients with newly diagnosed supratentorial malignant gliomas [abstract]. Neuro Oncol 2008, 10:1123.
41. McGirt M.J., Than K.D., Weingart J.D., et al. Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme. J Neurosurg 2009, 110:583-588.
42. Green R.M., Stewart D.J., Hugenholtz H., Richard M.T., Thibault M., Montpetit V. Human central nervous system and plasma pharmacology of mitoxantrone. J Neurooncol 1988, 6:75-83.
43. Boiardi A., Silvani A., Eoli M., et al. Treatment of recurrent glioblastoma: can local delivery of mitoxantrone improve survival?. J Neurooncol 2008, 88(May):105-113.
44. Voulgaris S., Partheni M., Karamouzis M., Dimopoulos P., Papadakis N., Kalofonos H.P. Intratumoral doxorubicin in patients with malignant brain gliomas. Am J Clin Oncol 2002, 25:60-64.
45. Boiardi A., Eoli M., Salmaggi A., et al. New approach in delivering chemotherapy: locoregional treatment for recurrent glioblastoma (rGBM). J Exp Clin Cancer Res 2003, 22:S123-S127.
46. Pöpperl G., Goldbrunner R., Gildehaus F.J., et al. O-(2-[18F]fluoroethyl)-l-tyrosine PET for monitoring the effects of convection-enhanced delivery of paclitaxel in patients with recurrent glioblastoma. Eur J Nucl Med Mol Imaging 2005, 32:1018-1025.
47. Reardon D.A., Akabani G., Coleman R.E., et al. Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. J Clin Oncol 2002, 20:1389-1397.
48. Reardon D.A., Akabani G., Coleman R.E., et al. Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results. J Clin Oncol 2006, 24:115-122.
49. Reardon D.A., Zalutsky M.R., Akabani G., et al. A pilot study: 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost. Neuro Oncol 2008, 10:182-189.
50. Reardon D.A., Quinn J.A., Akabani G., et al. Novel human IgG2b/murine chimeric antitenascin monoclonal antibody construct radiolabeled with 131I and administered into the surgically created resection cavity of patients with malignant glioma: phase I trial results. J Nucl Med 2006, 47:912-918.
51. 211At-labeled chimeric antitenascin monoclonal antibody 81C6. J Nucl Med 2008, 49:30-38.
52. Riva P., Franceschi G., Riva N., Casi M., Santimaria M., Adamo M. Role of nuclear medicine in the treatment of malignant gliomas: the locoregional radioimmunotherapy approach. Eur J Nucl Med 2000, 27:601-609.
53. Boiardi A., Bartolomei M., Silvani A., et al. Intratumoral delivery of mitoxantrone in association with 90-Y radioimmunotherapy (RIT) in recurrent glioblastoma. J Neurooncol 2005, 72:125-131.
54. Patel S.J., Shapiro W.R., Laske D.W., et al. Safety and feasibility of convection-enhanced delivery of Cotara for the treatment of malignant glioma: initial experience in 51 patients. Neurosurgery 2005, 56:1243-1252.
55. Kneifel S., Cordier D., Good S., et al. Local targeting of malignant gliomas by the diffusible peptidic vector 1,4,7,10-tetraazacyclododecane-1-glutaric acid-4,7,10-triacetic acid-substance p. Clin Cancer Res 2006, 12:3843-3850.
56. 188Re-labelled humanized monoclonal antibody anti-epidemal growth factor receptor, nimotuzumab, in the locoregional treatment of malignant gliomas. Nucl Med Commun 2008, 29:66-75.
57. Parney I.F., Kunwar S., McDermott M., et al. Neuroradiographic changes following convection-enhanced delivery of the recombinant cytotoxin interleukin 13-PE38QQR for recurrent malignant glioma. J Neurosurg 2005, 102:267-275.
58. Kunwar S., Prados M.D., Chang S.M., et al. Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group. J Clin Oncol 2007, 25:837-844.
59. Sampson J.H., Akabani G., Archer G.E., et al. Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors. Neuro Oncol 2008, 10:320-329.
60. Weber F., Asher A., Bucholz R., et al. Safety, tolerability, and tumor response of IL4-Pseudomonas exotoxin (NBI-3001) in patients with recurrent malignant glioma. J Neurooncol 2003, 64:125-137.
61. Weaver M., Laske D.W. Transferrin receptor ligand-targeted toxin conjugate (Tf-CRM107) for therapy of malignant gliomas. J Neurooncol 2003, 65:3-13.
62. Laske D.W., Youle R.J., Oldfield E.H. Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors. Nat Med 1997, 3:1362-1368.
63. Study of therapy with TransMID™ compared to best standard of care in patients with glioblastoma multiforme. Available at: [Accessed 22.12.09]. http://clinicaltrials.gov/ct2/show/NCT00083447.
64. Kratz F. Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. J Control Release 2008, 132:171-183.